French derma beauty brand debuts with four flagship products
L’Oréal India has introduced its globally acclaimed dermatological skincare brand La Roche-Posay (LRP) in the Indian market, adding on its L’Oréal Dermatological Beauty (LDB) division.
The initial product range will feature Mela B3 Serum, Anthelios (a UVA/UVB protection formulation), Cicaplast, and Effaclar. Prices will start at Rs 450 for a 7.5ml pack of Effaclar Duo+M Gel, going up to Rs 3,300 for Mela B3 Serum.
Founded in 1975 by pharmacist René Levayer in the French spa town of La Roche-Posay and acquired by L’Oréal in 1989, the brand has become one of the most recommended by dermatologists worldwide. Each product contains La Roche-Posay Thermal Spring Water, naturally rich in selenium, an antioxidant known for its soothing and skin-restoring properties.
Globally, La Roche-Posay reported EUR 2.9 billion in net sales in 2024, driven by its hero products such as Cicaplast Baume B5+ and Mela B3 Serum, with ambitions to surpass EUR 3 billion this year. The brand is currently the top growth driver for L’Oréal’s dermatological beauty segment.
“Every day, we drive dermatology forward by bringing together radical efficacy and profound human understanding, in close collaboration with the medical community. With La Roche-Posay’s legacy of life-changing dermatology, we are proud to bring the most advanced dermatological knowledge and innovation to India, empowering dermatologists and consumers to achieve healthier skin and better lives”, said Rami Itani, Director, L’Oréal Dermatological Beauty, L’Oréal India.
Following the introduction of CeraVe in 2023, La Roche-Posay became the second brand under L’Oréal’s Dermatological Beauty Division to enter India. The products will be exclusively available through dermatologist clinics, Nykaa, and Apollo 24|7.
